CD39/69 double negative TIL (Iovance Biotherapeutics)

N/A

Report date: 2025/06/11 10:53:41

Base Information

Drug NameCD39/69 double negative TIL (Iovance Biotherapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionEarly activation antigen CD69 modulatorsEctonucleoside triphosphate diphosphohydrolase 1 modulatorsT lymphocytes stimulants
TargetsEarly activation antigen CD69Ectonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIovance Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIovance Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A